Search
RDEA806
go.drugbank.com/drugs/DB05228InvestigationalRDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Miocamycin
go.drugbank.com/drugs/DB13287Approvedor as an alternative to erythromycin treatment [A176170]. … It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections
Talbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
Dexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnIt is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. … It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer.
Products: XIALOX® 200 MG, XIALOX® 100 MGVIR201
go.drugbank.com/drugs/DB05110ExperimentalThe aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
Dichloroacetic acid
go.drugbank.com/drugs/DB08809ApprovedInvestigationalWithdrawnDichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market
Survodutide
go.drugbank.com/drugs/DB18989InvestigationalSurvodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT
Camostat
go.drugbank.com/drugs/DB13729Investigational[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.
Imisopasem manganese
go.drugbank.com/drugs/DB04976InvestigationalM40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
AOD9604
go.drugbank.com/drugs/DB06388ExperimentalAOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.